Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company that combines large-scale experimental biology and chemistry with advanced computational infrastructure to increase the efficiency of drug discovery and development. By integrating automation, algorithms, and data-driven methods, Recursion seeks to decode biology and industrialize the R&D process.

Headquarters and Global Presence

Recursion is headquartered in Salt Lake City, Utah, where it is a founding member of BioHive, the region’s life-sciences collective. The company also maintains offices in Montréal, New York, London, and Oxford. Its workforce of approximately 600 employees spans both life-science and computational disciplines. Corporate governance distinguishes clearly between executive leadership and board oversight.

Recursion OS

The company’s core innovation, Recursion OS, is an end-to-end internal platform encompassing the entire drug discovery and development cycle — from target identification to clinical trials.

It generates and continuously updates massive, multi-layered datasets combining:

• Phenotypic screening,
• Transcriptomic and proteomic readouts,
• ADME data, and
• De-identified patient information from research partners.

Each week, millions of automated wet-lab experiments are conducted, producing high-dimensional biological data that are converted into computable representations. Using this information, machine learning and foundation models trained on Recursion OS create a searchable map of trillions of biological and chemical relationships.

LOWE Workflow Engine

LOWE is the workflow engine integrated into Recursion OS, providing scientists with a natural-language interface to access computational and experimental tools. It chains together complex, multi-step operations such as:

• Mapping biological relationships,
• Querying target–drug interactions through MatchMaker,
• Generative compound design and synthesis planning,
• ADMET prediction, compound procurement, and visualization.

This system reduces time and resource requirements in early-stage discovery by automating design-to-validation processes.

Computational and Experimental Infrastructure

On the experimental side, Recursion operates standardized, automation-driven workflows to ensure high-throughput and reproducibility.

On the computational side, it leverages cutting-edge hardware — notably BioHive-2, a supercomputer developed in partnership with NVIDIA — enabling large-scale data processing, model training, and search optimization at industrial scale.

Partnerships and Collaborations

Recursion collaborates with pharmaceutical companies and technology providers through a range of discovery and asset-development partnerships across oncology, neuroscience, immunology, and fibrosis.

When novel therapeutic uses for existing compounds are identified through the Recursion Map, the company evaluates opportunities for licensing or internal development.

Corporate Philosophy

Recursion’s guiding principle is the industrialization of drug discovery — transforming R&D into a standardized, automated, and data-connected process.

Its organizational values emphasize:

• Integrity and accountability,
• Time-sensitive execution,
• Direct and transparent communication,
• Cross-functional collaboration, and
• Continuous learning and improvement.

By linking standardization, data connectivity, and model-experiment feedback loops, Recursion aims to accelerate the path from hypothesis to clinical validation, redefining how medicines are discovered and developed.